113 related articles for article (PubMed ID: 37995739)
21. Humoral and cellular immune responses to Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in adolescents with liver transplantation: Single center experience.
Sánchez-Zapardiel E; Alós M; Nozal P; González-Muñoz M; Frauca-Remacha E; Gavilán LB; Quiles MJ; Hierro L; López-Granados E
Front Immunol; 2022; 13():1049188. PubMed ID: 36505469
[TBL] [Abstract][Full Text] [Related]
22. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies.
Heftdal LD; Hamm SR; Pérez-Alós L; Madsen JR; Armenteros JJA; Fogh K; Kronborg CC; Vallentin AP; Hasselbalch RB; Møller DL; Hansen CB; Pries-Heje M; Gang AO; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Iversen K; Garred P; Nielsen SD; Grønbaek K
Eur J Haematol; 2023 Aug; 111(2):229-239. PubMed ID: 37151174
[TBL] [Abstract][Full Text] [Related]
23. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
Front Immunol; 2022; 13():907615. PubMed ID: 35812459
[TBL] [Abstract][Full Text] [Related]
24. Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study.
Herzberg J; Fischer B; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
Front Immunol; 2022; 13():896151. PubMed ID: 35844588
[TBL] [Abstract][Full Text] [Related]
25. High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium.
Calcoen B; Callewaert N; Vandenbulcke A; Kerstens W; Imbrechts M; Vercruysse T; Dallmeier K; Van Weyenbergh J; Maes P; Bossuyt X; Zapf D; Dieckmann K; Callebaut K; Thibaut HJ; Vanhoorelbeke K; De Meyer SF; Maes W; Geukens N
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746728
[TBL] [Abstract][Full Text] [Related]
26. Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2.
Hayashi JY; Simizo A; Miyamoto JG; Costa LVS; Souza OF; Chiarelli T; Bacarov NBS; Hidalgo R; Garcia LD; Soane MM; Braconi CT; Maricato JT; Janini LM; Salomão R; Popi AF; Glezer I; Bonetti T; Tashima AK
J Infect; 2022 Jun; 84(6):834-872. PubMed ID: 35235810
[No Abstract] [Full Text] [Related]
27. Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.
Gulmez R; Ozbey D; Agbas A; Aksu B; Yildiz N; Uckardes D; Saygili S; Yilmaz EK; Yildirim ZY; Tasdemir M; Kiykim A; Cokugras H; Canpolat N; Nayir A; Kocazeybek B; Caliskan S
Pediatr Nephrol; 2023 Jul; 38(7):2199-2208. PubMed ID: 36459243
[TBL] [Abstract][Full Text] [Related]
28. Dynamics of the Cellular and Humoral Immune Response After BNT162b2 Messenger Ribonucleic Acid Coronavirus Disease 2019 (COVID-19) Vaccination in COVID-19-Naive Nursing Home Residents.
Van Praet JT; Vandecasteele S; De Roo A; Vynck M; De Vriese AS; Reynders M
J Infect Dis; 2021 Nov; 224(10):1690-1693. PubMed ID: 34514509
[TBL] [Abstract][Full Text] [Related]
29. Dynamics of humoral and cellular immunity elicited by the BNT162b2 mRNA vaccine in psoriatic patients under targeted immunosuppression: A longitudinal cohort study.
Zelini P; Isoletta E; Volontè M; Lilleri D; Cassaniti I; Musella V; Klersy C; Baldanti F; Brazzelli V
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e294-e296. PubMed ID: 36433886
[No Abstract] [Full Text] [Related]
30. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
[TBL] [Abstract][Full Text] [Related]
31. Is the BNT162b2 vaccine still effective against the latest variant: XBB.1.5?
Erdag E; Sultanoglu N; Ozverel CS
Niger J Clin Pract; 2023 Oct; 26(10):1519-1524. PubMed ID: 37929529
[TBL] [Abstract][Full Text] [Related]
32. Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study.
Sim W; Kang H; Jung J; Lee J; Ko GY; Park HS; Choi J; Park K; Oh EJ
Front Immunol; 2023; 14():1120556. PubMed ID: 36936965
[TBL] [Abstract][Full Text] [Related]
33. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination.
Iancovici L; Khateeb D; Harel O; Peri R; Slobodin G; Hazan Y; Melamed D; Kessel A; Bar-On Y
Rheumatology (Oxford); 2022 Aug; 61(8):3439-3447. PubMed ID: 34849628
[TBL] [Abstract][Full Text] [Related]
34. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
35. Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas.
Candon S; Lemee V; Leveque E; Etancelin P; Paquin C; Carette M; Contentin N; Bobee V; Alani M; Cardinael N; Lepretre S; Camus V; Bouclet F; Boulet E; Menard AL; Lanic H; Stamatoullas A; Lemasle E; Pepin LF; Richard D; Dubois S; Tilly H; Dalleac A; Plantier JC; Etienne M; Jardin F
Haematologica; 2022 Mar; 107(3):755-758. PubMed ID: 34854280
[No Abstract] [Full Text] [Related]
36. Humoral and Cellular Immune Response Elicited by Two Doses of mRNA BNT162b2 Vaccine Against SARS-CoV-2 in People Living with HIV.
Vanetti C; Milazzo L; Ardizzone F; Oreni L; Cappelletti G; Trabattoni D; Biasin M
AIDS Res Hum Retroviruses; 2023 Sep; 39(9):495-499. PubMed ID: 37031355
[TBL] [Abstract][Full Text] [Related]
37. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.
Romero-Olmedo AJ; Schulz AR; Hochstätter S; Das Gupta D; Virta I; Hirseland H; Staudenraus D; Camara B; Münch C; Hefter V; Sapre S; Krähling V; Müller-Kräuter H; Widera M; Mei HE; Keller C; Lohoff M
Nat Microbiol; 2022 Feb; 7(2):195-199. PubMed ID: 35013593
[TBL] [Abstract][Full Text] [Related]
38. The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV).
Woldemeskel BA; Karaba AH; Garliss CC; Beck EJ; Wang KH; Laeyendecker O; Cox AL; Blankson JN
Clin Infect Dis; 2022 Apr; 74(7):1268-1270. PubMed ID: 34293114
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
[TBL] [Abstract][Full Text] [Related]
40. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.
Gonzalez-Perez M; Montes-Casado M; Conde P; Cervera I; Baranda J; Berges-Buxeda MJ; Perez-Olmeda M; Sanchez-Tarjuelo R; Utrero-Rico A; Lozano-Ojalvo D; Torre D; Schwarz M; Guccione E; Camara C; Llópez-Carratalá MR; Gonzalez-Parra E; Portoles P; Ortiz A; Portoles J; Ochando J
Front Immunol; 2022; 13():845882. PubMed ID: 35401504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]